A5046708642- Venous Thromboembolism Diagnosis and Management
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Atrial Fibrillation Management and Outcomes
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Antiplatelet Therapy and Cardiovascular Diseases
- Eosinophilic Disorders and Syndromes
- Brain Metastases and Treatment
- Central Venous Catheters and Hemodialysis
- HER2/EGFR in Cancer Research
- Blood Coagulation and Thrombosis Mechanisms
- Acute Myeloid Leukemia Research
- Platelet Disorders and Treatments
- Chemotherapy-induced cardiotoxicity and mitigation
- Acute Lymphoblastic Leukemia research
- Lymphoma Diagnosis and Treatment
- Intracerebral and Subarachnoid Hemorrhage Research
- Cardiac tumors and thrombi
- Lung Cancer Treatments and Mutations
- Medication Adherence and Compliance
- Cerebrovascular and Carotid Artery Diseases
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Cancer Treatment and Pharmacology
- Inflammatory Biomarkers in Disease Prognosis
- Blood disorders and treatments
Tel Aviv University
2016-2025
Rabin Medical Center
2016-2025
Memorial Sloan Kettering Cancer Center
2023-2025
Cornell University
2024
Carmel Medical Center
2024
Institute of Hydrology of the Slovak Academy of Sciences
2023
University of Alabama at Birmingham
2023
Maastricht University
2017-2021
Icahn School of Medicine at Mount Sinai
2019
Meir Medical Center
2011-2015
Abstract Thrombo-inflammation describes the complex interplay between blood coagulation and inflammation that plays a critical role in cardiovascular diseases. The third Maastricht Consensus Conference on Thrombosis assembled basic, translational, clinical scientists to discuss origin potential consequences of thrombo-inflammation etiology, diagnostics, management patients with disease, including myocardial infarction, stroke, peripheral artery disease. This article presents state-of-the-art...
In cancer patients, thrombocytopenia can result from bone marrow infiltration or anticancer medications and represents an important limitation for the use of antithrombotic treatments, including anticoagulant, antiplatelet, fibrinolytic agents. These drugs are often required prevention treatment cancer-associated thrombosis cardioembolic in atrial fibrillation increasingly older population. Data indicate that remains independent risk factor even case thrombocytopenia, since mild-to-moderate...
It is unclear whether newly diagnosed cancer adds to the risk of arterial thromboembolism (ATE) in patients with atrial fibrillation/flutter (AF). This especially relevant for AF low intermediate CHA2DS2-VASc scores whom risk-benefit ratios between ATE and bleeding are delicately balanced.The objectives were evaluate a score 0 2 without cancer.A population-based retrospective cohort study was performed. Patients not receiving anticoagulation at diagnosis (or matched index date) included....
There are scarce data on venous thromboembolism (VTE) rates among non-small cell lung cancer (NSCLC) patients treated with immune-checkpoint inhibitors (ICI). The Khorana Score (KS), used to guide thromboprophylaxis in patients, was validated receiving chemotherapy.To assess VTE and KS performance NSCLC ICI or chemotherapy.We performed a retrospective cohort study of starting either platinum-based chemotherapy. 6-month cumulative incidence the chemotherapy cohorts hazard ratios (HR) 95%...
Tyrosine kinase inhibitors (TKIs) have revolutionized the prognosis of chronic myeloid leukemia. With advent highly efficacious therapy, focus has shifted toward managing TKI adverse effects, such as vascular events (VAEs). We used an in vitro angiogenesis model to investigate TKI-associated VAEs. Our data show that imatinib, nilotinib, and ponatinib reduce human umbilical vein endothelial cells (HUVECs) viability. Pharmacological concentrations induced apoptosis, reduced migration,...
The contemporary literature on the relationship between serum TSH levels and osteoporotic fractures in euthyroid individuals is limited by conflicting results analyses conducted a small number of fractures.Our objective was to examine association normal range variation incidence hip male female patients aged 65 years or older.We performed population-based historical prospective cohort study within Clalit Health Services population.Clalit members ≥65 with at least 1 measurement during year...
The tyrosine kinase inhibitors (TKIs), nilotinib, ponatinib, and dasatinib (but not bosutinib or imatinib), are associated with vascular adverse events (VAEs) in chronic myeloid leukemia (CML). Though the mechanism is inadequately understood, an effect on cells has been suggested. We investigated of imatinib, dasatinib, bosutinib, ponatinib tube formation, cell viability, gene expression human endothelial (HUVECs). found a distinct genetic profile HUVECs treated nilotinib compared to who...
Abstract Atherothrombosis is a leading cause of cardiovascular mortality and long-term morbidity. Platelets coagulation proteases, interacting with circulating cells in different vascular beds, modify several complex pathologies including atherosclerosis. In the second Maastricht Consensus Conference on Thrombosis, this theme was addressed by diverse scientists from bench to bedside. All presentations were discussed audience members results these discussions incorporated final document that...
Abstract Direct oral anticoagulants (DOACs) are increasingly prescribed in treatment of cancer-associated thrombosis, but limited data exist regarding safety DOACs patients with brain metastases. We aimed to determine the incidence intracranial hemorrhage (ICH) metastases receiving or low-molecular-weight heparin (LMWH) for venous thromboembolism atrial fibrillation. An international 2-center retrospective cohort study was designed. Follow-up started on first day concomitant anticoagulation...
Not available.